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Expression of salt and urea transporters in rat kidney during by its potential renal toxicity leading to acute renal fail-
cisplatin-induced polyuria. ure [1–3]. CP also induces a dose-related renal toxicity
Background. Cisplatin (CP) induced polyuria in rats is asso- in laboratory animals. The nephrotoxicity induced by CPciated with a reduction in medullary hypertonicity, normally
typically manifests as a reduction in glomerular filtrationgenerated by the thick ascending limb (TAL) salt transporters,
and the collecting duct urea transporters (UT). To investigate rate [elevation in blood urea nitrogen (BUN) and serum
the molecular basis of this abnormality, we determined the creatinine levels], polyuria, a marked defect in urine
protein abundance of major salt and UT isoforms in rat kidney concentrating ability, proteinuria, hyperuricemia, andduring CP-induced polyuria.
frequently magnesium wasting [4]. Pathologically, bothMethods. Male Sprague-Dawley rats received either a single
injection of CP (5 mg/kg, N  6) or saline (N  6) intraperito- in humans and laboratory animals, the site of CP-induced
neally five days before sacrifice. Urine, blood, and kidneys were damage is the S3 segment (pars recta) of the proximal
collected and analyzed.
tubule [5–7].Results. CP-treated rats developed polyuric acute renal fail-
However, the most salient and persistent features ofure as assessed by increased blood urea nitrogen (BUN), urine
volume and decreased urine osmolality. Western analysis of kid- CP-induced nephrotoxicity are polyuria and inability to
ney homogenates revealed a marked reduction in band density concentrate urine. CP-induced polyuria, following a sin-
of the bumetanide-sensitive Na-K-2Cl cotransporter in cortex
gle non-lethal dose in rats, occurs in two distinct phases.(60% of control values, P 0.05), but not in outer medulla (OM)
The early polyuria, which occurs when the glomerular(106% of control values). There were no differences in band
densities for the renal outer medullary potassium channel filtration rate (GFR) is still normal (1 to 2 days following
(ROMK), the type III Na-H exchanger (NHE3), the -subunit the injection of CP), is due to impaired release of arginine
of Na,K-ATPase in the OM; or for UT-A1, UT-A2 or UT-A4
vasopressin (AVP) or antidiuretic hormone from thein outer or inner medulla. However, the band pattern of UT-A2
pituitary gland. This early polyuria can be reversed byand UT-A4 proteins in the OM of CP-treated rats was different
from the control rats, suggesting a qualitative modification of the administration of AVP [4, 8]. On the other hand, the
these proteins. late-phase polyuria, which occurs when the GFR is lowConclusions. Changes in the abundance of outer or inner
(5 to 6 days following injection of CP), is resistant tomedullary salt or urea transporters are unlikely to play a role
in the CP-induced reduction in medullary hypertonicity. How- AVP administration. Studies have shown that this CP-
ever, qualitative changes in UT proteins may affect their func- induced end-organ resistance to AVP is associated with
tionality and thus may have a role. a decrease in medullary hypertonicity [9, 10] and reduced
cAMP generation in the medullary collecting ducts [11].
Recently, we demonstrated that the CP-induced poly-Cisplatin (CP; cis-dichlorodiammine platinum II) is a
uria in rats is also associated with a significant decreasepotent anticancer agent, especially in the treatment of
in the expression of collecting duct [aquaporins 2 and 3solid tumors. However, its clinical use is often limited
(AQP2 and AQP3)], and proximal nephron and micro-
vascular (AQP1) water channels in inner medulla [12].Key words: medullary hypertonicity, urea concentration gradient,
nephrotoxicity, thick ascending limb, loop of Henle, acute renal failure. While the decreased expression of these water chan-
nels alone can account for the loss of urinary concen-
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eration of an osmotic gradient by thick ascending limb barbital overdose. Blood was collected by cardiac punc-
ture. Then both kidneys were quickly removed and placed(TAL) salt transporters and a urea concentration gradi-
ent by the urea transporters (UT) [13]. The latter is in ice-cold sterile phosphate-buffered saline (PBS) in
petri dishes. Cortex, outer and inner medulla were dis-dependent on efficient recycling of urea between the
descending thin limb of Henle’s loop and the inner med- sected as described previously [12]. Briefly, kidneys were
gently decapsulated and cut across into four to five piecesullary collecting duct (IMCD) [14]. However, the most
prominent abnormality of solute transport during CP- and kept in ice-cold PBS. From each piece, the cortical
tissue was excised from the rest of the medulla using theinduced polyuria is the lack of addition of urea to fluid
in the loop of Henle. Instead, urea is reabsorbed from differential coloration of the corticomedullary junction
as a landmark. Then the reddish outer medulla, includingthe loop fluid, resulting in a reversal of the urea concen-
tration gradient in the medulla [4]. the outer and inner stripes, was separated from the white
papillary portion or inner medulla of the kidney. To en-To investigate the molecular basis of the CP-induced
decrease in medullary hypertonicity, we determined the sure consistency, the sharp dissection of different regions
of the kidneys was performed under a dissection micro-abundance of the major salt transporters of the TAL
and several UT isoforms in rat kidney following a single scope by only one of us (BKK). The different regions of
kidney thus dissected were flash frozen in liquid nitrogennon-lethal dose of CP (5 mg/kg body wt). For these
studies semiquantitative immunoblotting was performed before storing at 75C. Kidney samples containing all
three regions were also fixed for histological examinationusing specific antibodies to the bumetanide-sensitive
Na-K-2Cl cotransporter (BSC1 or NKCC2), the type by immersing them in neutral-buffered 10% formalin.
III Na-H exchanger (NHE3), the renal outer medullary
Analysis of blood and urine samples and assay ofpotassium channel (ROMK), the alpha-subunit of so-
tissue platinum levelsdium-potassium ATPase (-Na,K-ATPase), and three
different UT isoforms (UT-A1, UT-A2, UT-A4), all These were performed as described previously [12].
Blood urea nitrogen (BUN) concentration was deter-products of UT-A gene [15–18]. UT-A1 is expressed in
the inner medullary collecting duct principal cells and mined colorimetrically using a commercially available
kit (Sigma Chemical Co., St. Louis, MO, USA). Twenty-UT-A2 is found in the thin descending limb of Henle
[19, 20]. Both these are important sites in the recycling four-hour urine samples were assayed for volume and
osmolality. Platinum levels in the renal cortex were as-of urea and thus for generation of the urea concentration
gradient in the deep inner medulla. The tubule localiza- sayed by flameless atomic absorption spectroscopy as
described previously [12, 23].tion of UT-A4 has not yet been clearly determined. Of
these proteins, BSC1, ROMK and UT-A2 have been
Antibodies and immunoblottingshown to be up-regulated in abundance by vasopressin
or water restriction [20–22]. Peptide-derived, affinity purified polyclonal antibod-
ies to AQP2, AQP3, NHE3, BSC1, ROMK, and UT-A
and monoclonal antibody to -Na,K-ATPase were used
METHODS
in this study. The antibody to AQP2 (GN-762) was raised
Animals and treatment using a C-terminal peptide sequence originally designed
and published by Dr. Mark A. Knepper [24]. This anti-Male Sprague-Dawley rats weighing 260 to 310 g (Har-
lan Sprague-Dawley, Indianapolis, IN, USA) were housed body has been previously characterized by immuno-
blotting and immunocytochemistry [12, 25]. Likewise,two per cage, and had free access to drinking water and
standard rat chow. They were maintained on 12-hour the antibody to BSC1 (NKCC2) was raised against an
N-terminal peptide sequence originally designed and pub-light/dark cycles and were acclimated to the housing
conditions for a few days prior to the experimental proce- lished by Dr. Knepper [26]. BSC1 antiserum was affinity
purified on a column bound with immobilized immuniz-dures. One day prior to the treatment (day 0), baseline
24-hour urine samples were collected by placing the ani- ing peptide, and was characterized by immunoblotting
(Kishore et al, unpublished data). Antibodies against themals in individual metabolic cages. The next day (day 1),
the rats were randomly divided into two groups (N  6 AQP3, NHE3, and ROMK were kindly provided by Dr.
Knepper, and were characterized previously [22, 27, 28].per group). One group was injected intraperitoneally
with 5 mg/kg body weight CP (Alfa Products, Ward Hill, A monoclonal antibody against the -subunit of Na,K-
ATPase was purchased (Upstate Biotechnology, LakeMA, USA) in a volume of 0.5 to 0.6 mL normal saline
(CP-treated group). The other group was injected with Placid, NY, USA). Peptide-derived polyclonal antibody
against UT-A was raised and characterized previouslyan equal volume of normal saline alone (control group).
On day 4, the animals were again placed in metabolic [29]. This antibody was made to a 19 amino acid region
in the carboxy-terminal part of the protein. Thus, due tocages and a second 24-hour urine sample was collected.
On day 5, all the rats were euthanized by sodium pento- the shared C-terminal sequence, the UT-A antibody iden-
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Table 1. Body weight, urine volume, urine osmolality, blood urea nitrogen (BUN) and tissue platinum levels in control and
cisplatin (CP)-treated rats
Controls CP-treated
Parameter Day 0 Day 5 Day 0 Day 5
Body weighta % of day 0 100.01.7 108.02.2b 100.01.0 99.01.9
Urine volume mL/24 h 8.90.8 9.20.9 9.60.5 41.73.9c
Urine osmolality mOsm/kg H2O 1854148 1963139 158967 50058c
BUN mg/dL — 19.751.30 — 70.026.75d
Platinum in cortex lg/g dry tissue — 4.950.78 — 40.704.65d
All values are mean  SEM, N  6 per group.
a As percentage of respective day 0 values, where 100% is equivalent to 297 g in controls and 271 g in CP-treated rats
b P  0.05 vs. corresponding day 0 values
c P  0.001 vs. corresponding day 0 values
d P  0.001 vs. corresponding control values
tifies UT-A1, UT-A2 and UT-A4 isoforms [30]. Whole Quantitation of mRNA and protein levels
tissue homogenates were prepared from the cortex, outer Autoradiograms from the Northern analysis were scan-
or inner medullary tissue samples of each rat and solubi- ned and the bands were quantitated (versus GAPDH) by
lized by the methods described earlier [12, 31]. Immu- densitometry using IS1000 Digital Imaging System and
noblotting of the solubilized tissue proteins was per- its associated software (Alpha Innotech Corporation,
San Leandro, CA, USA). Immunoblots were scannedformed according to the methods described previously
using laser densitometry and images were semiquantita-[12, 29, 32, 33].
tively analyzed by standard software [32, 33].
Nucleic acid probes and Northern hybridization:
Histopathological examination
An RNA probe that hybridizes with UT-A1, UT-A2
Kidney samples were fixed in neutral-buffered 10%and UT-A4 mRNA was synthesized as follows. The
formalin for two days at room temperature, transferredprobe template UT-A4 cDNA was inserted into the plas-
to methanol, and then embedded in paraffin. Five-
mid pcDNA3, which has a flanking SP6 promoter site. micrometer thick sections were cut on a microtome and
Following linearization at the BamHI restriction site, a stained with hematoxylin and eosin for conventional
32P-labeled RNA probe was synthesized by in vitro tran- histopathological examination.
scription. The resulting probe included the last 410 bp
Statistical analysisof the 3 end of the cDNA coding region of UT-A4. Due
to isoform homology, the probe detects common se- All quantitative data are expressed as mean  SEM.
quences in UT-A2, UT-A4 and UT-A1. Total RNA was Differences among the means of multiple groups of data
extracted from outer medullary tissue samples using Tri- (body wt, urine analysis) were analyzed by one-way anal-
ysis of variance (ANOVA) followed by Tukey-KramerReagent (Molecular Research Center, Inc., Cincinnati,
Multiple Comparison test. Differences between two groupsOH, USA) as described previously [12]. Ten micrograms
of data (blood analysis, tissue platinum levels, quantita-of total RNA from each sample was chemically and heat
tion of blots) were analyzed by the unpaired t test. Pdenatured and electrophoresed on 1% agarose gels in
values of less than 0.05 were considered significant.glyoxal buffer. The size fractionated RNA was then blot-
ted to nylon membranes, UV cross-linked, and probed.
Membranes were prehybridized at 68C for 30 minutes, RESULTS
and then hybridized with 32P-labeled probe for two hours Body weight
at 68C. Then the membranes were washed twice in low
Table 1 presents the body weights in control and CP-
stringency solution for five minutes at 45C, followed by treated groups of rats. The control group showed a sig-
two 15-minute washings in high stringency solution at 68 nificant 8% increase in the body weight (P  0.05) five
to 70C. All Northern solutions were purchased from days after the initiation of the experiment. On the other
Ambion Inc. (Austin, TX, USA). The membranes were hand, the CP-treated group did not show any increase
exposed to standard x-ray film for 14 hours. As a control in the body weight.
for loading, membranes were probed with a 32P-labeled
Urine analysiscDNA probe for glyceraldehyde 3-phosphate dehydrog-
enase (GAPDH), synthesized by in vitro transcription Table 1 shows urine volumes and osmolalities at the
initiation (day 0) and completion (day 5) of the study.from a linearized Triplescript plasmid (Ambion).
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Fig. 1. Representative microphotographs show-
ing cisplatin-induced histopathological alter-
ations in the kidney. Formalin fixed and paraf-
fin embedded kidneys were sectioned (5 m
thickness) and stained with hematoxylin-eosin.
(A) A low magnification profile of corticomed-
ullary junction of the kidney in a control rat.
(B) Corresponding region at the same magni-
fication, in a CP-treated rat. Note the striking
differences in the profiles between the CP-
treated rat and the control rat. Cisplatin treat-
ment was associated with loss of tubular archi-
tecture and integrity and hypercellularity of the
interstitium in the corticomedullary junction.
Most tubules in this region were also dilated
and filled with debris from necrosed cells. (C)
A high magnification profile of S3 segments
of proximal tubules in a control rat. (D) The
corresponding segments at the same magnifi-
cation in a CP-treated rat. S3 segments of proxi-
mal tubules in CP-treated rat showed evidence
of tubular dilatation, necrosis, loss of microvilli
and sloughing, and were filled with debris. The
interstitial spaces were often found studded
with leukocytes (short and thick arrow) and
lots of red blood cells in the blood vessels (long
arrow).
The 24-hour urine volumes in the control group were had 8.2-fold higher mean platinum level in the cortex,
indicating that the renal cortex of these rats accumulatednot different on day 0 versus day 5. These volumes were
large amounts of the injected drug.also not different from the urine collected on day 0 from
the CP-treated group. However, the CP-treated group
Histopathological examinationshowed a 4.3-fold increase in urine volume on day 5 as
Conventional histopathological examination using lightcompared to day 0 values, indicating a severe polyuric
microscopy on hematoxylin-eosin stained paraffin sec-condition. The urine osmolality in the control group on
tions showed striking differences between the CP-treatedday 5 was not different from the day 0 values. On the
rat kidneys and the control rat kidneys. At low magnifi-other hand, CP-treated rats showed 3.2-fold decrease in
cation, these differences were localized in the deep cor-urine osmolality on day 5, as compared with the values
tex and corticomedullary junction (compare Fig. 1 A andon day 0 in the same group, thus indicating a severe
B). In the CP-treated rats, the proximal tubules showedimpairment of urinary concentrating ability.
clear evidence of tubular dilatation, necrosis, loss of mi-
crovilli, and vacuolization, with surrounding areas ofBlood urea nitrogen and tissue platinum levels
hypercellularity. The superficial cortex, however, ap-
Table 1 shows the BUN and the platinum levels in peared to be free from such alterations (not shown). At
renal cortex. The control group showed mean BUN level higher magnification, the lumen of the S3 segments of
in the normal range. The mean BUN level in the CP- proximal tubules in CP-treated rat kidneys were seen
treated group was 3.5-fold higher than the control group, filled with debris of necrosed cells, often with evidence
indicating a severe renal functional impairment. Pre- of interstitial infiltration of blood cells (compare Fig. 1
viously we showed that in CP-treated rats platinum accu- C and D). At the magnifications we could achieve with
mulates in the cortex and outer medulla to the same the light microscope, no histologic alterations could be
extent [12]. Hence, our current study assayed the cortical detected in inner medulla (not shown).
samples only for platinum levels and saved the outer
Immunoblotting studiesmedullary samples for other assays. The mean back-
ground level of platinum in the cortex by our assay sys- To examine the effect of CP treatment on the protein
abundance of water channels (AQP2 and AQP3), salttem was 4.95  0.78 g/g dry tissue. CP-treated rats
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Fig. 3. Effect of cisplatin treatment on the relative abundance of the
bumetanide-sensitive Na-K-2Cl cotransporter (BSC1 or NKCC2) of the
thick ascending limb. Immunoblots were loaded with equal amounts
of total protein from each rat (10 g cortex homogenates, A; 2 g
of outer medullary homogenates, B). Each lane was loaded with sample
from a different rat. Both immunoblots were probed with anti-BSC1
polyclonal antibody. Cisplatin treatment significantly decreased BSC1
relative abundance in the cortical thick ascending limb, but had noFig. 2. Effect of cisplatin treatment on the relative abundances of aqua-
apparent effect on medullary thick ascending limb.porins 2 (AQP2, A) and aquaporin 3 (AQP3, B) in the inner medulla
of rats. Immunoblots were loaded with equal amounts (20 g) of total
protein from inner medullary homogenates prepared from vehicle-
(controls) and cisplatin (CP)-treated rats. Each lane was loaded with
sample from a different rat. The blot in panel A was probed with poly-
clonal antibody against AQP2, while the panel B blot was probed with
anti-AQP3 antibody. Both AQP2 and AQP3 proteins were significantly
decreased by cisplatin treatment.
(BSC1, ROMK, NHE3 and -Na,K-ATPase) and urea
(UT-A1, UT-A2, and UT-A4) transporters, we used a
semiquantitative immunoblotting approach, which had
been well characterized in our laboratories [12, 29, 32,
33]. The protein abundance of AQP2 (Fig. 2A) and
AQP3 (Fig. 2B) water channels in inner medulla of con-
trol and CP-treated rats are shown. As we demonstrated
previously [12], CP treatment resulted in a marked de-
crease in the protein abundance of these collecting duct
water channels in the inner medulla. The decrease in
the vasopressin-regulated AQP2 water channel protein
abundance was reflected both in the native (29 kD) and Fig. 4. Effect of cisplatin treatment on the relative abundance of three
additional thick ascending limb salt transporters in outer medulla. Im-glycosylated (35 to 45 kD) bands. Densitometry data
munoblots were loaded with equal amounts of total protein from outer
showed that the mean band density for AQP2 (native 	 medullary homogenates of each rat. Each lane was loaded with samples
from a different rat. (A) The immunoblot (loaded with 5 g proteinglycosylated bands) in CP-treated rats was decreased to
from each sample) was probed with anti-NHE3 antibody. (B) The44% (P 0.003) of the mean values in controls, whereas immunoblot (loaded with 10 g protein from each sample) was probed
that of AQP3 was reduced to 50% (P  0.001) of the with anti-ROMK antibody. (C) The immunoblot (loaded with 5 g
protein from each sample) was probed with anti--Na,K-ATPase mono-corresponding values in controls. These values are com-
clonal antibody. There were no significant differences in relative abun-
parable to the ones that we reported earlier for AQP2 dance of NHE3 or -Na,K-ATPase. However, the 70 kD band associ-
ated with ROMK was apparently up-regulated by cisplatin treatment.(33%) and AQP3 (69%) in the inner medulla of CP-
treated rats [12].
The protein abundance of BSC1 (NKCC2) in the cor-
tex (Fig. 3A) and outer medulla (Fig. 3B) is shown. BSC1 value in controls (P  0.007). The corresponding change
is expressed only in thick ascending limb cells from the for outer medulla was 106% (P  0.755).
outer medulla into the cortex. The protein abundance Figure 4 shows immunoblots of outer medullary ho-
of BSC1 was markedly decreased in the cortex, while it mogenates probed with antibodies against NHE3, ROMK
was not affected in the outer medulla. Densitometry of and the -subunit of Na,K-ATPase. Relative abundance
the bands revealed that in the CP-treated group, band of these proteins in the cortical thick ascending limbs
could not be assessed by this method because these pro-density in the cortex was reduced to 60% of the mean
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Fig. 6. Effect of cisplatin treatment on the relative expression of UT-A2
and UT-A4 mRNA in outer medulla. Northern blots were prepared
by loading 10 g of outer medullary total RNA from 4 control and 4
CP-treated rats. Each lane was loaded with sample from one rat. The
RNA blots were hybridized with a 32P-labeled RNA probe that detects
UT-A2 (3.1 kb) and UT-A4 (2.7 kb) transcripts. In the lower panel
a 32P-labeled probe detects glyceraldehyde phosphate dehydrogenase
(GAPDH; used as a reference in densitometric measurements). Cis-
platin treatment did not result in significant alterations in the expression
levels of UT-A2 or UT-A4 mRNA in the outer medulla.
Fig. 5. Effect of cisplatin treatment on the relative abundance of the
UT-A isoforms in outer medulla (A) or inner medulla (B). Immunoblots
were loaded with equal amount (10 g) of total protein from the outer
Northern analysisor inner medullary homogenates of each rat. Each lane was loaded with
sample from a different rat. The blots were probed with a polyclonal Since the immunoblotting approach revealed an ap-anti-UT-A1 antibody that recognized UT-A1, UT-A2 and UT-A4. The
parent qualitative difference in the UT-A2 or UT-A4relative abundance of UT-A1, UT-A2 or UT-A4 proteins in the outer
or inner medulla did not show any significant differences. However, protein expression in the outer medulla, the Northern
the pattern of UT-A2/UT-A4 smear in the outer medulla of CP-treated analysis was carried out to search for alterations in thegroup was different from the one in controls (panel A).
mRNA expression for these two proteins. Figure 6 shows
the results of these Northern hybridization experiments,
teins are also expressed in other tubule segments, which using an RNA probe that hybridizes with both UT-A2
would be contained in the cortex homogenate. The band (3.1 kb) and UT-A4 (2.7 kb) transcripts. Normalization
density of NHE3 (Fig. 4A) in CP-treated group did not of the densitometric data using the expression of GAPDH
show any significant change (114% of controls, P  mRNA as a control for loading, did not reveal any
0.451). The 45 kD protein band of ROMK (Fig. 4B) also changes in the expression levels of UT-A2 (117% of
did not show any change (118% of controls, P  0.740). controls) or UT-A4 (96% of controls).
This band is considered to be specific for ROMK [22].
However, in the CP-treated rats, the 70 kD protein band
DISCUSSIONshowed a significant increase (135% of controls, P 
Cisplatin is an anti-neoplastic agent commonly used0.0001). The identity of this 70 kD band when immu-
in chemotherapy of solid tumors. However, the repeatednoblots are probed with the anti-ROMK antibody, L567,
use of this drug is limited by its potent and irreversiblehas not been established [22]. Finally, the band density
nephrotoxicity, which has residual effects often manifest-of the -subunit of Na,K-ATPase (Fig. 4C) was not al-
ing as persistent polyuria and impaired urinary concen-tered by CP-treatment (120% of controls, P  0.39).
tration ability, among others [4]. These effects of cisplatinFigure 5 shows the band densities of UT-A isoforms
on the urinary concentration mechanism cannot be cor-(UT-A1, UT-A2 and UT-A4) in the outer and inner
rected by the administration of vasopressin, and thusmedullas of control and CP-treated rats. UT-A1 has two
have been attributed to an end organ resistance to vaso-specific bands associated with it [34], one at approxi-
pressin [8]. Recently, we showed that CP-induced poly-mately 117 and one at approximately 97 kD. In the inner
uria in rats is associated with a marked reduction in themedulla, the 117 kD band did not show any change
relative abundance of the collecting duct water channel(Fig. 5B). However, the 97 kD band in CP-treated group
proteins, aquaporins 2 and 3 [12]. These proteins areshowed a modest, but not significant, decrease (76% of
primarily responsible for the rapid transcellular reab-controls, P  0.08; Fig. 5B). The UT-A2/UT-A4 protein
sorption of water along the collecting duct so that urineband smear (35-50 kD) did not show any change in the
can be concentrated. However, another component ofouter or inner medulla (Fig. 5). However, the pattern of
urine concentration is the generation and maintenancethese bands in the outer medulla markedly and consis-
of the corticomedullary salt gradient established by thetently differed between the control and CP-treated
active transport of sodium out of the thick ascendinggroups (Fig. 5A), indicating a possible qualitative change
in the expression of these proteins. limb and into the interstitium by various transport pro-
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teins, such as, BSC1/NKCC2, ROMK and Na,K-ATPase. to relative expression of salt transporters. We found no
differences between cisplatin-treated and vehicle-treatedSimilarly, a urea concentration gradient is generated in
the deep inner medulla by urea transporters of IMCD, rats for the relative abundance of the 45 kD band associ-
ated with the renal outer medullary potassium channel,for example, UT-A1 and in the thin descending limb of
Henle, UT-A2. Vasopressin not only increases the water ROMK, the 161 kD band associated with Na-K-2Cl co-
transporter, BSC1, the 85 kD band associated with thepermeability of the collecting duct, but also stimulates
the active NaCl transport in TAL and increases the urea sodium hydrogen exchanger, NHE3, or the 95 kD band
associated with the -subunit of Na,K-ATPase. These arepermeability in the terminal IMCD. Hence the end organ
resistance to vasopressin may involve one or more of the major transporters responsible for the generation
and maintenance of medullary osmotic gradients. How-these regulatory mechanisms responsible for the overall
urinary concentration ability of the kidney. Thus, we ever, there was a significant increase in the 70 kD band
associated with ROMK (Fig. 4). Unfortunately, we can-investigated whether alterations in the abundance of these
major salt and urea transport proteins could be responsi- not interpret this finding further, because when the anti-
ROMK antibody used in these studies was character-ble for the vasopressin-resistant polyuria and impaired
urinary concentration ability in cisplatin toxicity. ized [22] it was not clear if this band represented ROMK,
or ROMK bound to another protein, or alternatively, aOur current studies lead to three other major conclu-
sions. First of all, the abundance of the key sodium and similarly-structured, but different, cross-reacting pro-
tein. A lack of change in relative protein abundance doespotassium transporters of the medullary thick ascending
limb, namely the bumetanide-sensitive Na-K-2Cl co- not negate the possibility that there were changes in
protein function as a result of perhaps trafficking and/ortransporter, (BSC1/NKCC2), the renal outer medullary
potassium channel (ROMK), the sodium hydrogen ex- phosphorylation. For example, direct phosphorylation
of ROMK by protein kinase A has been shown to bechanger, type III (NHE3), and the-subunit of the Na,K-
ATPase are not decreased during cisplatin toxicity. Thus, necessary for full activation [36]. Similarly, Plata et al
have shown that the C4 isoform of NaK2Cl cotrans-changes in abundance of these transporters are unlikely
to play any role for the decreased corticomedullary os- porter, (BSC1) is regulated by protein kinase A [37]. In
addition, BSC1 protein may be regulated by intracellularmotic gradient observed in cisplatin toxicity. Secondly,
although there was no difference in the relative abun- trafficking, because BSC1 has been detected within sub-
apical vesicles [38].dance for BSC1 with cisplatin toxicity in the outer med-
ulla, in the cortex BSC1 was markedly reduced in ab- The relative difference in sensitivity of BSC1 in the
cortical TAL versus medullary TAL in cisplatin toxicityundance following cisplatin treatment. This indicates
regional differences in the sensitivity of the TAL to cis- was striking (Fig. 3). Different isoforms of BSC1 were
expressed in different portions of the TAL [39]. Theseplatin toxicity, and may explain the cisplatin-induced
impairment of urinary dilution capacity as discussed be- isoforms were regulated differently. In addition the ex-
tracellular environment in the cortical TAL may be dif-low. Finally, while there were no differences in the over-
all abundance for the three major urea transporter iso- ferent in the cisplatin-treated rats versus that of the med-
ullary TAL, due to the necrosis of pars recta (S3)forms that we evaluated, that is, UT-A1, UT-A2, and
UT-A4, there was a qualitative change in the nature of the proximal tubules, resulting in interstitial infiltration
(Fig. 1). Furthermore, the Na-K-2Cl cotransporter is in-bands on immunoblots after CP treatment. The UT-A2/
UT-A4 bands appeared consistently “smudgy,” which volved in the urinary dilution process [40], and a de-
creased abundance of this transporter in the cortexmight indicate greater variation in glycosylation or other
post-translational modifications of these proteins. These should affect the urinary diluting capacity. In fact, Gor-
don, Peterson and Anderson demonstrated that follow-variations in protein modifications possibly alter their
functionality. The following paragraphs further elabo- ing a water load, cisplatin-treated rats have a significantly
lowered ability to excrete water and could not dilute therate on these findings.
Similar to our earlier studies [12], in the current studies urine to the same extent as the control animals [10].
Thus, our current observation of decreased abundancethe injection of a single dose of cisplatin to rats resulted
in polyuric acute renal failure as assessed by blood and of BSC1 protein in the cortex of cisplatin-treated rats
provides a molecular basis for the earlier functional ob-urine analyses. This was associated with marked decrease
in the expression of AQP2 and AQP3 water channel servations of Gordon et al.
The renal excretion of urea, the most abundant urinaryproteins in the inner medulla as reported in our earlier
study [12]. Similar observations on the decreased expres- solute, is not simple. It involves complex movements of
this solute between renal tubules and microvasculature,sion of AQP2 and AQP3 in cisplatin-treated rat kidneys
were reported more recently by Kim et al [35]. resulting in the generation and maintenance of a urea
concentration gradient in the deep inner medulla. ThisOur study shows that the medullary TAL cells are fairly
resistant to the toxicity of cisplatin, at least with regard urea concentration gradient facilitates the osmotic trans-
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port of free water across the terminal IMCD, and thus In conclusion, “vasopressin resistance” has been asso-
aids in the urinary concentration process. The vasopres- ciated with cisplatin toxicity. This relative resistance
sin-regulated UT-A1 in the terminal IMCD delivers might be the mechanism for the down regulation in abun-
large quantities of urea to the deepest portion of the dance for both aquaporins 2 and 3, since the abundance
inner medullary interstitium. UT-A2, a splice variant of of these proteins is increased in response to conditions
UT-A1, localized in the descending thin limbs of Henle’s of high circulating vasopressin levels, such as water re-
loop [20] facilitates the recycling of urea from the inner striction or infusion of vasopressin or its agonists [43].
medullary interstitium into the loop of Henle. Our semi- In fact, the resistance of collecting ducts to vasopressin
quantitative immunoblotting studies with specific poly- in cisplatin toxicity was shown to be associated with
clonal antibody that identifies the UT-A1, UT-A2 and reduced cAMP generation, as a result of a defect in the
UT-A4 isoforms revealed no significant alterations in G protein-mediated signaling [11, 35]. Because several
the protein abundance of these transporters. Thus, alter- of the proteins examined here are also known to be
ations in the abundance of these proteins are unlikely increased in abundance by vasopressin (ROMK, BSC1,
to play any role in the reversal of the urea concentration UT-A2), it is rational to predict that these proteins, as
gradient seen in cisplatin toxicity. However, it appears well, would be down-regulated with vasopressin resis-
that the UT-A2 and/or UT-A4 proteins in cisplatin toxic- tance. However, that does not seem to be the case. In
ity might be modified, since their appearance on Western this context, it is not clear if cells other than collecting
blot differed and both proteins contain consensus se- duct cells develop vasopressin resistance with cisplatin
quences for glycosylation [30]. Future studies should de- toxicity. Definitely more studies are needed to under-
termine whether glycosylation affects the function of stand the cellular and molecular mechanisms of vaso-
UT-A2 or UT-A4, and whether it is altered by cisplatin pressin resistance and decreased medullary hypertonicity
administration. Another possibility that could explain in cisplatin toxicity.
the difference in the Western blot results was that the
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